How to buy Bicycle Therapeutics stock - 21 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Bicycle Therapeutics stock

Own Bicycle Therapeutics stock in just a few minutes.

Bicycle Therapeutics plc is a biotechnology business based in the US. Bicycle Therapeutics shares (BCYC) are listed on the NASDAQ and all prices are listed in US Dollars. Bicycle Therapeutics employs 87 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Bicycle Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BCYC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Bicycle Therapeutics share price

Use our graph to track the performance of BCYC stocks over time.

Bicycle Therapeutics shares at a glance

Information last updated 2021-03-24.
52-week range$12.31 - $33.00
50-day moving average $26.58
200-day moving average $21.84
Wall St. target price$36.75
PE ratio 1839
Dividend yield N/A (0%)
Earnings per share (TTM) $-14.16

Buy Bicycle Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Bicycle Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Bicycle Therapeutics under- or over-valued?

Valuing Bicycle Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bicycle Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Bicycle Therapeutics's P/E ratio

Bicycle Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1839x. In other words, Bicycle Therapeutics shares trade at around 1839x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Bicycle Therapeutics financials

Revenue TTM $10.4 million
Gross profit TTM $-22,759,000
Return on assets TTM -23.94%
Return on equity TTM -54.08%
Profit margin 0%
Book value $5.33
Market capitalisation $598.7 million

TTM: trailing 12 months

Shorting Bicycle Therapeutics shares

There are currently 441,460 Bicycle Therapeutics shares held short by investors – that's known as Bicycle Therapeutics's "short interest". This figure is 10.3% up from 400,080 last month.

There are a few different ways that this level of interest in shorting Bicycle Therapeutics shares can be evaluated.

Bicycle Therapeutics's "short interest ratio" (SIR)

Bicycle Therapeutics's "short interest ratio" (SIR) is the quantity of Bicycle Therapeutics shares currently shorted divided by the average quantity of Bicycle Therapeutics shares traded daily (recently around 159949.27536232). Bicycle Therapeutics's SIR currently stands at 2.76. In other words for every 100,000 Bicycle Therapeutics shares traded daily on the market, roughly 2760 shares are currently held short.

However Bicycle Therapeutics's short interest can also be evaluated against the total number of Bicycle Therapeutics shares, or, against the total number of tradable Bicycle Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bicycle Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Bicycle Therapeutics shares in existence, roughly 20 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Bicycle Therapeutics shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bicycle Therapeutics.

Find out more about how you can short Bicycle Therapeutics stock.

Bicycle Therapeutics share dividends

We're not expecting Bicycle Therapeutics to pay a dividend over the next 12 months.

Bicycle Therapeutics overview

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site